Los Angeles Capital Management & Equity Research Inc. cut its holdings in Stryker Corporation (NYSE:SYK) by 3.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,350 shares of the medical technology company's stock after selling 800 shares during the quarter.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. San Francisco Sentry Investment Group CA raised its stake in shares of Stryker by 47.8% in the third quarter. Fifth Third Bancorp now owns 223,753 shares of the medical technology company's stock worth $29,457,000 after buying an additional 1,619 shares during the period. Lcnb Corp acquired a new position in shares of Stryker in the 1st quarter valued at about $204,000. Weatherstone Capital Management now owns 2,393 shares of the medical technology company's stock worth $315,000 after acquiring an additional 46 shares in the last quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company's stock worth $143,000 after acquiring an additional 325 shares during the last quarter.
In related news, insider Lonny J. Carpenter sold 5,000 shares of the stock in a transaction that occurred on Friday, November 3rd. Commerzbank Aktiengesellschaft FI now owns 49,160 shares of the medical technology company's stock worth $6,982,000 after acquiring an additional 38,293 shares during the last quarter. Three equities research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and four have issued a buy recommendation on the company. Robert W. Baird raised Stryker from a "neutral" rating to an "outperform" rating and raised their price objective for the stock from $161.00 to $173.00 in a research note on Thursday, November 16th. Finally, Stifel Nicolaus upped their price target on Stryker from $151.00 to $158.00 and gave the stock a buy rating in a report on Friday, July 28th. Needham & Company LLC raised Stryker from an "underperform" rating to a "hold" rating in a research note on Friday, August 25th. Royal Bank Of Canada reissued a "buy" rating and issued a $155.00 price target on shares of Stryker in a research note on Monday, October 2nd. Finally, Oppenheimer restated a "hold" rating on shares of Stryker in a research report on Wednesday, August 23rd. The stock has an average rating of Hold and an average target price of $152.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 7.40% of the company's stock.
Stryker Corporation (SYK) traded up $0.98 during trading on Thursday, reaching $155.73. The stock had a trading volume of 1,090,543 shares, compared to its average volume of 1,181,132. Stryker Corporation has a one year low of $108.29 and a one year high of $160.62. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.37 and a quick ratio of 1.61. The stock has a market capitalization of $56,895.34, a price-to-earnings ratio of 24.09, a P/E/G ratio of 2.39 and a beta of 0.78.
Stryker Corporation (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 EPS for the quarter, topping analysts' consensus estimates of $1.50 by $0.02. The transaction is expected to be dilutive to Stryker's 2018 adjusted net earnings per diluted share  by approximately $0.04 and accretive thereafter. The company had revenue of $19.11 million during the quarter, compared to analyst estimates of $19.61 million. On average, analysts forecast that Entellus Medical will post ($1.36) EPS for the current year. Stryker's revenue was up 6.1% on a year-over-year basis.